OBJECTIVE: Investigate the association between neoadjuvant treatment strategy and perioperative complications in patients undergoing proctectomy for nonmetastatic rectal cancer. SUMMARY OF BACKGROUND DATA: Neoadjuvant SC-TNT is an alternative to neoadjuvant CRT for rectal cancer. Some have argued that short-course radiation and extended radiation-to-surgery intervals increase operative difficulty and complication risk. However, the association between SC-TNT and surgical complications has not been previously investigated. METHODS: This single-center retrospective cohort study included patients undergoing total mesorectal excision for nonmetastatic rectal cancer after SC-TNT or CRT between 2010 and 2018. Univariate analysis of severe POM and multiple secondary outcomes, including overall POM, intraoperative complications, and resection margins, was performed. Logistic regression of severe POM was also performed. RESULTS: Of 415 included patients, 156 (38%) received SC-TNT and 259 (62%) received CRT. The cohorts were largely similar, though patients with higher tumors (69.9% vs 47.5%, P < 0.0001) or node-positive disease (76.9% vs 62.6%, P = 0.004) were more likely to receive SC-TNT. We found no difference in incidence of severe POM (9.6% SC-TNT vs 12.0% CRT, P = 0.46) or overall POM (39.7% SC-TNT vs 37.5% CRT, P = 0.64) between cohorts. Neoadjuvant regimen was also not associated with a difference in severe POM (odds ratio 0.42, 95% confidence interval 0.04-4.70, P = 0.48) in multivariate analysis. There was no significant association between neoadjuvant regimen and any secondary outcome. CONCLUSION: In rectal cancer patients treated with SC-TNT and proctectomy, we found no significant association with POM compared to patients undergoing CRT. SC-TNT does not significantly increase the risk of POM compared to CRT.
OBJECTIVE: Investigate the association between neoadjuvant treatment strategy and perioperative complications in patients undergoing proctectomy for nonmetastatic rectal cancer. SUMMARY OF BACKGROUND DATA: Neoadjuvant SC-TNT is an alternative to neoadjuvant CRT for rectal cancer. Some have argued that short-course radiation and extended radiation-to-surgery intervals increase operative difficulty and complication risk. However, the association between SC-TNT and surgical complications has not been previously investigated. METHODS: This single-center retrospective cohort study included patients undergoing total mesorectal excision for nonmetastatic rectal cancer after SC-TNT or CRT between 2010 and 2018. Univariate analysis of severe POM and multiple secondary outcomes, including overall POM, intraoperative complications, and resection margins, was performed. Logistic regression of severe POM was also performed. RESULTS: Of 415 included patients, 156 (38%) received SC-TNT and 259 (62%) received CRT. The cohorts were largely similar, though patients with higher tumors (69.9% vs 47.5%, P < 0.0001) or node-positive disease (76.9% vs 62.6%, P = 0.004) were more likely to receive SC-TNT. We found no difference in incidence of severe POM (9.6% SC-TNT vs 12.0% CRT, P = 0.46) or overall POM (39.7% SC-TNT vs 37.5% CRT, P = 0.64) between cohorts. Neoadjuvant regimen was also not associated with a difference in severe POM (odds ratio 0.42, 95% confidence interval 0.04-4.70, P = 0.48) in multivariate analysis. There was no significant association between neoadjuvant regimen and any secondary outcome. CONCLUSION: In rectal cancer patients treated with SC-TNT and proctectomy, we found no significant association with POM compared to patients undergoing CRT. SC-TNT does not significantly increase the risk of POM compared to CRT.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila Journal: Lancet Oncol Date: 2015-07-14 Impact factor: 41.316
Authors: Robert J Myerson; Benjamin Tan; Steven Hunt; Jeffrey Olsen; Elisa Birnbaum; James Fleshman; Feng Gao; Lannis Hall; Ira Kodner; A Craig Lockhart; Matthew Mutch; Michael Naughton; Joel Picus; Caron Rigden; Bashar Safar; Steven Sorscher; Rama Suresh; Andrea Wang-Gillam; Parag Parikh Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-15 Impact factor: 7.038
Authors: R Maréchal; B Vos; M Polus; T Delaunoit; M Peeters; P Demetter; A Hendlisz; A Demols; D Franchimont; G Verset; P Van Houtte; J Van de Stadt; J L Van Laethem Journal: Ann Oncol Date: 2011-10-29 Impact factor: 32.976
Authors: Andrea Cercek; Campbell S D Roxburgh; Paul Strombom; J Joshua Smith; Larissa K F Temple; Garrett M Nash; Jose G Guillem; Philip B Paty; Rona Yaeger; Zsofia K Stadler; Kenneth Seier; Mithat Gonen; Neil H Segal; Diane L Reidy; Anna Varghese; Jinru Shia; Efsevia Vakiani; Abraham J Wu; Christopher H Crane; Marc J Gollub; Julio Garcia-Aguilar; Leonard B Saltz; Martin R Weiser Journal: JAMA Oncol Date: 2018-06-14 Impact factor: 31.777
Authors: Amit Roy; Pawinee Mahasittiwat; Ashley A Weiner; Steven R Hunt; Matthew G Mutch; Elisa H Birnbaum; Ira J Kodner; Thomas E Read; James W Fleshman; Jeffrey R Olsen; Robert J Myerson; Parag J Parikh Journal: Pract Radiat Oncol Date: 2016-08-31
Authors: K Bujko; L Wyrwicz; A Rutkowski; M Malinowska; L Pietrzak; J Kryński; W Michalski; J Olędzki; J Kuśnierz; L Zając; M Bednarczyk; M Szczepkowski; W Tarnowski; E Kosakowska; J Zwoliński; M Winiarek; K Wiśniowska; M Partycki; K Bęczkowska; W Polkowski; R Styliński; R Wierzbicki; P Bury; M Jankiewicz; K Paprota; M Lewicka; B Ciseł; M Skórzewska; J Mielko; M Bębenek; A Maciejczyk; B Kapturkiewicz; A Dybko; Ł Hajac; A Wojnar; T Leśniak; J Zygulska; D Jantner; E Chudyba; W Zegarski; M Las-Jankowska; M Jankowski; L Kołodziejski; A Radkowski; U Żelazowska-Omiotek; B Czeremszyńska; L Kępka; J Kolb-Sielecki; Z Toczko; Z Fedorowicz; A Dziki; A Danek; G Nawrocki; R Sopyło; W Markiewicz; P Kędzierawski; J Wydmański Journal: Ann Oncol Date: 2016-02-15 Impact factor: 32.976
Authors: Per J Nilsson; Boudewijn van Etten; Geke A P Hospers; Lars Påhlman; Cornelis J H van de Velde; Regina G H Beets-Tan; Lennart Blomqvist; Jannet C Beukema; Ellen Kapiteijn; Corrie A M Marijnen; Iris D Nagtegaal; Theo Wiggers; Bengt Glimelius Journal: BMC Cancer Date: 2013-06-07 Impact factor: 4.430